Is Galleri the future of cancer treatment? It's not that simple. The new research from the company, while promising, isn't ...
MyRisk TestSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary ...
Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced ...
Panelists discussed these questions during a recent Institute for Value-Based Medicine® event held in Nashville, Tennessee, ...
Investigators analyzed exfoliated cells in urine test specimens to identify 50 candidate RNAs for prostate cancer detection.
Please provide your email address to receive an email when new articles are posted on . The study will evaluate whether two multicancer early detection tests improve early detection of 10 solid tumors ...
Erratum: Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors We conducted a cross-sectional qualitative study using grounded ...
Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback